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Abstract
Background Salusins are recently identified endogenous bio-
active peptides that have hypotensive and bradycardiac ef-
fects. Salusin-β is involved in the pathogenesis of human
atherosclerosis.
Methods This was a prospective cohort study of a young
patient population with hypertension (HTN). Based on ambu-
latory blood pressure monitoring (ABPM), the adolescents
were categorized into two groups, namely, a hypertensive
group consisting of patients with essential (primary) HTN
(HTN group) and a group consisting of patients with white-
coat HTN [reference (R) group]. Correlations between serum
salusin-β level and clinical, laboratory and ambulatory blood
pressure (BP) variables were assessed.
Results The median salusin-β concentration was significantly
higher in patients with essential HTN than in those with white-
coat HTN (R group). Salusin-βwas positively correlated with
the body mass index Z-score, systolic and diastolic blood
pressure (BP) from three independent measurements, mean
systolic BP during the daytime, triglyceride (TG) level, and
atherogenic index (TG/high-density lipoprotein-cholesterol
ratio).
Conclusions The results of this preliminary study suggest that
salusin-β may play an important role in the pathogenesis of
HTN in a young population. Further research should focus on
the role of salusin-β in the mechanism of essential HTN and
the assessment of possible correlations between salusin-β and
other well-knownmarkers of atherosclerosis in both teenagers
and adults. This research should serve as a base for future
studies in this field.
Keywords Salusin-β . Essential hypertension . Atherogenic
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Introduction
Salusins are recently identified endogenous bioactive peptides
which were first discovered by bioinformatic analysis of a
full-length complementary DNA library [1]. Human salusin-α
and -β are related peptides of 28 and 20 amino acids, respec-
tively, produced from the same precursor, prosalusin [2]. It has
been confirmed that salusins exist in human plasma in their
originally predicted forms [3, 4], indicating their possible role
as peptide hormones in humans [2]. They represent a new
class of bioactive peptides with hypotensive and bradycardiac
effects, among which salusin-β is the most potent. Salusins
are multifunctional regulators of hemodynamics [1]. The role
of salusins in hypertension (HTN) and atherosclerosis has not
yet been clearly established.
Salusin-αmay be involved in the pathogenesis of essential
(primary) HTN [5], and salusin-β, which is theoretically
synthesized concomitantly with salusin-α, causes profound
hypotension without exerting an appreciable vasodilatory ef-
fect [5]. The hypotensive effect of salusins is achieved partly
through activation of the parasympathetic nervous system [1],
and elevated sympathetic nervous system activation has been
shown in HTN [5]. Chronic increased sympathetic respon-
siveness may lead to essential HTN [5]. Salusin-β stimulates
the release of arginine-vasopressin (AVP) and oxytocin from
the rat neurohypophysis [6, 7]. Bolus injection of salusin-β
induces rapid and temporary hypotension and bradycardia via
a cholinergic mechanism and has direct negative inotropic
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effects; however salusin-β has no vasodilatory effect [1]. To
the contrary, salusin-β induces potent hypotension via nega-
tive inotropic and chronotropic actions [2]. Circulating levels
of salusin-β are standardly higher than those of salusin-α, but
patients with essential HTN show significant but slightly
lower levels than healthy volunteers [8]. Salusin-α, on the
other hand, shows distinctly lower levels in essential HTN [8],
which is a common risk factor for cardiovascular disease [5].
Atherosclerosis, which is often observed in the early stage
of essential HTN [5], is a pathological injury-to-response
process that is initiated by early inflammatory responses of
the vascular endothelial cells [9]. HTN-induced mechanical
stimuli, such as pressure overload, stretch, and shear stress,
cause arterial endothelial injury, leading to the development of
atherosclerosis [2]. Vasoactive agents, such as angiotensin II,
urotensin II, and serotonin, all of which are agonists of G-
protein–coupled receptors, play key roles as mediators linking
HTN and atherosclerosis [10]. Salusins play an important role
as endogenous modulators of atherogenesis [8]. Salusin-β
exerts systemic proatherogenic activity, while salusin-α has
a contrasting anti-atherogenic effect [8]. These two peptides
induce opposite effects on macrophage foam cell formation
[11]. Salusin-α suppresses foam cell formation, while
salusin-β stimulates it [11]. In contrast to salusin-β,
salusin-α has marginal mitogenic effects in vascular smooth
muscle cells [1] and fibroblasts [2]. Reduced levels of serum
salusin-α could be a reliable biomarker for detecting cardio-
vascular disease rather than increased salusin-β levels [8].
Salusins may be involved in both the maintenance of
hemodynamic homeostasis and the regulation and develop-
ment of human atherosclerosis [2].
The aim of this study was to test the hypothesis that serum
salusin-α and salusin-β levels differ in adolescents with es-
sential HTN compared to those of a reference group. An
additional aim was to investigate the correlations between
salusin-α, salusin-β and clinical, laboratory, and blood pres-
sure (BP) monitoring variables.
Patients and methods
This was a prospective cohort study of children and adoles-
cents with essential (primary) HTN. The study cohort com-
prised 88 children (33 girls, 55 boys) aged 6–18 years who
had been referred to the Department of Pediatrics and Ne-
phrology, The Medical University of Białystok, Poland, be-
tween July 2010 and March 2014 by general practitioners.
The majority of patients had elevated BP and were hospital-
ized to confirm or rule out the diagnosis of HTN.
Based on ambulatory blood pressure monitoring (ABPM)
we categorized the children and adolescents into two groups.
One group comprised 58 patients with essential HTN (43
boys, 15 girls; age range 6–18 years), and the second group
was a reference (R) group consisting of 30 patients (12 boys,
18 girls; age range 7–17.5 years) with white-coat HTN.
Inclusion criteria were: age between 6 and 18 years; essen-
tial arterial HTN verified by ABPM as mean daytime and
nighttime systolic BP (SBP) levels of ≥95th percentile for age,
sex, and height, and a load SBP (LSBP) or load diastolic BP
(LDBP) of >25 % [12]; normal levels of creatinine. Exclusion
criteria were secondary forms of HTN; renal or hepatic dys-
function; heart failure; diabetes mellitus; hematological dis-
ease; systemic inflammatory conditions; autoimmune dis-
eases; girls on contraceptive pills; subjects treated with hyper-
tensive agents and medications known to affect BP values.
In the patients placed in the R group, essential HTN was
excluded during the medical examination on the basis of
ABPM (mean daytime and nighttime SBP and DBP levels
of <95th percentile for age, sex, and height and a LSBP and
LDBP of <25 %). Patients in the R group were not receiving
any medication at the time of the examination, and their
family history was negative for essential HTN or other car-
diovascular diseases, diabetes, and metabolic syndrome.
For all subjects, careful clinical histories were taken, and
physical examinations were performed. Height was measured
in duplicate (when the between measurements exceeded
4 mm, a third measurement was taken) using a pediatric
wall-mounted stadiometer, with the patient in a standing po-
sition with no shoes. Body weight was recorded with the
patient wearing only lightweight underwear to the nearest
0.05 kg, using a digital medical scale. The body mass index
(BMI) was calculated as weight (in kilograms) divided by the
square of height (meters squared). The exact age of each
patient was calculated from birth and examination dates.
Age- and height-specific reference values for BMI and height
were generated by the least mean squares method [13], which
characterizes the distribution of a variable by its median (M),
the coefficient of variation (S, i.e., the ratio of the standard
deviation and mean), and skewness (L) required to transform
the data to normality. Evaluation of these parameters was
obtained by a maximum-likelihood curve-fitting algorithm
to the original data plotted over the independent variable.
The formula for calculating the Z-score of BMI or height
was: LMS – SDS = {[Y/M (t)] L (t)-1}/[L (t) x S (t)], where
SDS in the standard deviation score, Y is the individual
observation, and L (t), M (t), and S (t) are the specific values
of L, M, and S, respectively, interpolated for the child’s age
and gender. The LMS values were taken from the OLAF study
published by Kulaga et al. [14].
After 12 h of overnight fasting, blood samples were taken
from each patient for the measurement of salusin-α and -β
levels, morphology of the peripheral blood, basal glucose
level, lipid profile, and serum creatinine, urea, and uric acid
levels. The serum salusin-α and -β levels were measured
using a commercially available ELISA kit (USCN Life Sci-
ence Inc., Houston, TX) according to the manufacturer’s
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instructions. In brief, this assay employs the competitive inhi-
bition enzyme immunoassay technique. A competitive inhibi-
tion reaction was launched between biotin-labeled salusin-α
or -β and unlabeled salusin-α or -β, with the pre-coated
antibody specific to salusin-α or -β, respectively. Next, avidin
conjugated to horseradish peroxidase was added to each mi-
croplate well, and the intensity of color of each sample after
the “stop” reaction was measured at 450 nm by a microtiter
plate reader and compared with a standard curve. Serum
salusin-β levels were expressed in picograms per milliliter,
but the serum salusin-α level was lower than the method
detection level (sensitivity) and therefore undetectable. Serum
creatinine was determined by the Jaffé reaction, and uric acid
was measured using a Hitachi apparatus (Hitachi, Chiyoda,
Japan). The morphology of the peripheral blood was assessed
on a Coulter analyzer MAXM (Beckman Coulter, Brea, CA).
Serum cholesterol, high-density lipoprotein (HDL)-cholester-
ol, and triglycerides (TG) were determined by the enzymatic
method using a Hitachi model 912 apparatus. Serum glucose
was measured with the Integra 800 analyzer (Roche Diagnos-
tics, Mannheim, Germany). ABPM was performed using the
SpaceLabs Medical oscillometric blood pressure monitor
(SpaceLab, Redwood, WA). The monitors were programmed
to measure BP every 15 min during the daytime (8 a.m. to
10 p.m.) and every 30 min during the nighttime (10 p.m. to
8 a.m.); however, the periods were corrected according to the
subjects’ diaries. Recording started between 8 and 9 a.m. and
lasted for 24 h. Recordings with a minimum 80 % of mea-
surements and without breaks of >2 h were considered to be
sufficient for analysis. The mean SBP and DBP were calcu-
lated separately for the 24-h period and for the awake and
asleep periods. We also analyzed the LSBP and LDBP during
the day and night. HTN diagnosed on the basis of ABPM was
defined as the mean daytime or nighttime SBP or DBP of
≥95th percentile and LSBP or LDBP daytime or nighttime
levels of >25 % [12]. The values were adjusted by gender and
body height according to the reference values provided by
Wühl et al. [15]. Each subject or his guardian was asked to
record the bedtime and time of awakening. After 24 h, the cuff
and monitor were removed and the data downloaded using the
manufacturer’s software.
The protocol was approved by the Bioethics Committee of
The Medical University of Białystok in accordance with the
Declaration of Helsinki. Informed consent was obtained from
parents or guardian of all participants and children older than
16 years.
Statistical methods
Data analysis was performed using the computer program
Statistica 10.0 PL (StatSoft, Tulsa, OK). Discrete variables
were expressed as counts (percentage), whereas continuous
variables were expressed as the median and range, unless
stated otherwise. The two groups were compared using the
Mann–Whitney test for data not distributed normally. Corre-
lations between salusin-β and other variables (clinical and
laboratory parameters) were evaluated using standard
methods, such as the Spearman’s test. The value of p<0.05
was considered to be statistically significant.
Results
Our study was conducted among 88 children and adolescents
who were divided into two groups based on the diagnosis of
essential (primary) HTN or not (white-coat HTN). The demo-
graphic, clinical, and and ambulatory BP data for each group
are summarized in Table 1.
The median age did not differ between groups. The major-
ity of patients in both HTN groups were male, which is in line
with available reports in this area [16]. More boys than girls
were diagnosed with essential HTN and placed in the HTN
group [43/58 (74.1 %) vs.15/58 (25.9 %), respectively],
whereas girls were in the majority in the R group (18/30,
60 %). The median BMI Z-score in the HTN group was
1.55 [interquartile range (IQR) 0.88–2.11] and statistically
significantly higher than the median BMI Z-score of the
reference group (p<0.01). Of the 58 patients in the HTN
group, 37 teenagers (63.8 %) were classified as overweight
or obese. It should be noted that there were clear differences
between the two study groups in that the hypertensive group
(HTN) consisted predominantly of adolescent boys with a
high BMI Z-score while the R group included many slender
girls with white-coat HT.
A comparison of both groups revealed that the patients in
the HTN group had higher serum levels of TG, Cr, and uric
acid. We found no significant differences in plasma glucose,
total cholesterol- and HDL-cholesterol concentrations be-
tween both groups. Data from the 24-h ABPM are shown in
Table 2.
Following the data presented in Table 2, we noticed signif-
icantly higher values of mean SBP and DBP (3 independent
measurements), mean SBP during 24 h of ABPM and sepa-
rately during the daytime and nighttime, and mean LSBP (%)
during daytime.
The median salusin-β concentration was significantly
higher in patients with essential HTN than in the subjects of
the R group [446.43 (IQR 280.87–631.3) vs. 350.3 (IQR
256.4–434.3) pg/mL, respectively; p<0.05], as shown on
Fig. 1. The serum level of salusin- in both groups was below
the method detection level (sensitivity).
Salusin-β was positively correlated with the BMI Z-score
(rho=0.23, p<0.05) and with the SBP and DBP from three
independent measurements [(rho=0.36, p<0.01;, rho=0.23,
p<0.05), respectively]. The relationship between serum
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salusin-β level and mean SBP during the daytime was derived
(rho=0.26, p<0.05), but we found no significant correlation
between serum salusin-β level and daytime DBP, SBP and
DBP during the nighttime and 24-h ABPMmonitoring, LSBP
and LDBP during the daytime and nighttime, and the SBP and
DBP daytime and nighttime drop. We also found a positive
relationship between salusin-β and TG level (rho=0.23,
p<0.05) and between salusin-β and atherogenic index (TG/
HDL-cholesterol ratio) (rho=0.22, p<0.05). The results are
shown on Figs. 2–5.
Discussion
In this study group, children and adolescents with essential
(primary) HTN had a significantly higher serum salusin-β
level than those assigned to the reference (R) group consisting
of patients with white-coat HTN. We also found a positive
correlation between the salusin-β blood level and the BMI Z-
score, SBP, and DBP, based on three independent measure-
ments, and between the mean SBP during 24-h ABPM and the
daytime and nighttime separately, TG, and the TG/HDL ratio
(atherogenic index). To our best knowledge this is the first
clinical study which focuses on the association between serum
salusin-β level and BP in children and adolescents. The serum
salusin- level in our participants was below the method de-
tection limit (sensitivity), and currently no published data on
serum salusin-α levels are available in the pediatric patient
population.
Salusins are considered to be multifunctional regulators of
hemodynamics [1]. Serum salusin-α levels are significantly
decreased in adult hypertensive patients relative to normoten-
sive controls [5], and this peptide is associated with preclinical
atherosclerotic markers in essential HTN [5]. Salusin-β acute-
ly regulates hemodynamics and chronically induces athero-
sclerosis [17]. This peptide is expressed in the brain and
Table 1 Anthropometric, clinical, and metabolic characteristics of the study cohort according to the diagnosis, or not, of essential (primary)
hypertensiona
Anthropometric, clinical, and metabolic characteristics HTN group (n = 58) R group (n = 30) p
Sex (M/F) 43/15 12/18 –
Age (years) 16 (13.6–17) 15 (12.6–17) NS
BMI Z-score 1.55 (0.88–2.11) 0.38 (−0.25 to 0.84) <0.01
Mean SBP (mmHg)b 134 (127.2–139) 115.5 (110–123) <0.01
Mean DBP (mmHg)b 76 (72.5–85) 64.5 (61–70) <0.01
Glucose (mg/dL) 90 (85–95) 90.5 (83.2–93.7) NS
Cholesterol (mg/dL) 172 (146.2–194) 162 (142–189) NS
Triglyceride (mg/dL) 100 (66–137) 80 (67–88) <0.05
HDL-cholesterol (mg/dL) 52 (43–62) 46 (40.5–62) NS
Triglyceride/HDL-cholesterol ratio 1.78 (1.11–2.83) 1.85 (0.88–2.10) NS
Creatinine (mg/dL) 0.72 (0.57–0.86) 0.61 (0.48–0.73) <0.01
Uric acid (mg/dL) 5.91 (5.03–6.71) 4.55 (3.57–5.57) <0.01
Salusin-β (pg/mL) 446.43 (280.87–631.3) 350.3 (256.4–434.3) <0.05
Values are presented as the median with the interquartile range (IQR: Q1–Q3) in parenthesis
M,Male; F, female; BMI Z-score, bodymass index age- and height-specific reference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL,
high-density lipoprotein; NS, Not significant
a The group of patients diagnosed with essential (primary) hypertension (HTN) were classified into the HTN group; the subjects diagnosed with white-
coat HTN were classified into the reference ®) group
bMean of three readings/measurements
Table 2 Ambulatory blood pressure monitoring data
Parameters HTN ( (n = 58) R ( (n = 30) p
Mean SBP/24 h (mmHg) 132 (127–137) 112 (110–114) <0.05
Mean DBP/24 h (mmHg) 72 (67–75) 64.5 (63.7–65.2) NS
Mean SBP/D (mmHg) 134 (129–140) 114 (111–116) <0.05
Mean SBP/N (mmHg) 120 (112–125) 104 (102–105) <0.05
Mean DBP/D (mmHg) 62 (58–66) 67 (67–67) NS
Mean DBP/N (mmHg) 62.72 (49–90) 58.5 (56–60) NS
LSBP (%) D 58.5 (44–73.2) 8.65 (5.8–11.4) <0.05
LSBP (%) N 50 (23–80) 8.35 (4.1–12.5) NS
LDBP (%) D 15.1 (6.8–24) 3.05 (1.5–4.5) NS
LDBP (%) N 11 (0–27) 13.5 (6.7–20.2) NS
SBP N drop (%) 11.8 (9–15.1) 8.85 (8.2–9.4) NS
DBP N drop (%) 14.7 (9.9–20.5) 12.6 (9.2–16) NS
Values are presented as the median with the IQR in parenthesis
LSBP/LDBP, load of SBP/DBP, respectively; D, day; N, night
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various peripheral tissues [18] and is synthesized ubiquitously
in human, rat, and mouse tissues, including the vasculature,
central nervous system, and kidneys [1, 19, 20]. Salusin-β has
also been shown to be present in human plasma and urine [4,
21, 22], indicating their possible role as peptide hormones in
humans [7, 8, 23, 24]. Locally, salusins are synthesized in the
fibroblast cells of the media in the aorta, but also in the smooth
muscle cells of the media in the left internal mammary artery
and saphena [25].
Very recent data indicate that neuroendocrine sources con-
tribute only in a very limited manner to peripheral total
salusin-β levels in humans [17]. However, because the major
origin of total plasma salusin-β levels is not the neuroendo-
crine system, it should be under the control of as-yet uniden-
tified systemic tissues/cells which produce and secrete the
salusin-β peptide [17]. It was recently discovered that periph-
eral salusin-β levels are derived from non-pituitary sources
[17]. Circulating salusin-β may be mostly bound to plasma
proteins and thus devoid of potent hemodynamic activity.
Circulating free salusin-β may function as a cardiotropic
peptide hormone that modulates hemodynamics in humans
[2, 6].
Sato et al. showed that the circulating level of salusin-β in
human is significantly but slightly lower in patients with
essential HTN than in healthy volunteers [8]. In this same
study, circulating salusin-β levels increased in patients with
coronary artery disease [8]. In our pediatric population the
serum level of salusin-β was higher in the HTN group than in
the R group, possibly due to the increased BMI and higher
frequency of obesity in the patients of the HTN group.
Fig. 1 Comparison of salusin-β
serum level (exponential increase)
between the hypertensive subjects
(HT) and the reference (R)
subjects with white-coat HTN
(p<0.05). Thick black horizontal
lineMedian, top and bottom of
box interquartile range (IQR:
Q1–Q3), filled circles outliers,
whiskers standard deviation (SD)
Fig. 2 Correlation between
serum salusin-β level and body
mass index (BMI) Z-score. BMI
Z-score BMI age- and height-
specific reference
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BP is regulated by many factors, such as vascular structure,
fluid volume, sympathetic nervous system, and the renin–
angiotensin system (RAS) [26]. Salusin-β, when injected as
a bolus, induces dose-dependent, rapid, and temporary hypo-
tension and bradycardia via a cholinergic mechanism and also
has direct negative inotropic cardiac effects and chronotropic
actions without a vasodilatory effect [1, 2, 27]. Salusin-β–
induced hypotension and bradycardia can be completely
blocked by pretreatment with atropine, a muscarinic receptor
antagonist, but not by propranolol [2, 27].
Our understanding of the mechanisms related to central
neural regulation of BP has progressed rapidly in recent years
[28]. Neuroendocrine salusin-β is localized in the vasopressin-
expressing neurons of the rat posterior pituitary and hypothal-
amus, which has tempted many authors to speculate its neural
secretion into the systemic circulation via axon terminals [1, 4,
7, 19, 20, 29]. Many studies have shown that salusin-β may
participate in the regulation of BP in coordinated manner with
arginine–vasopressin (AVP) [29]. Salusin-β stimulates the se-
cretion of AVP from the rat neurohypophysis in vitro in a
concentration-dependent manner [1] and coexists with AVP
in the hypothalamo-neurohypophyseal system of the rat under
normal conditions [29]. These findings suggest that salusin-β
has the potential to act as a neuropeptide that regulates body
fluid homeostasis via its modulation of AVP release [7]. Mi-
croinjection of salusin-β into the paraventricular nucleus
(PVN) increases BP via the release of norepinephrine and
AVP in renovascular hypertensive rats [8, 30]. This action is
apparently different from the depressor response determined by
intravenous administration of salusins. These unexpected
Fig. 3 Correlation between
serum salusin-β level and systolic
and diastolic blood pressure (BP)
(SBP andDBP, respectively) from
three independent measurements.
3× Three independent, duplicate
measurements
Fig. 4 Correlation between
serum salusin-β level and
triglyceride (TG) content (rho=
0.23, p<0.05)
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findings may be explained by the observation that salusin-β
level and the number of salusin-β-like immunopositive neu-
rons in the rostral ventrolateral medulla (RVLM), which is a
central vasomotor center that plays a critical role in the regula-
tion of sympathetic outflow and BP [31], have been found to be
greatly increased in hypertensive rats compared to normoten-
sive rats [18]. A number of researchers have shown that
salusin-β in the RVLM does not stimulate AVP release from
both the RVLM and neurohypophysis, but rather activates the
presympathetic neurons in the RVLM, which in turn increases
renal sympathetic activity (RSNA), median arterial pressure
(MAP) and heart rate (HR) [18]. Salusin-β has been observed
to increase RSNA, MAP, and HR in a dose-related manner in
model of hypertensive rats, but it failed to induce any signifi-
cant effect in normotensive rats [18]. However, salusin-β in the
PVN not only increases the plasma AVP level, which partially
contributes to the pressor response, but also increases AVP
release from the RVLMvia the projection from PVN toRVLM,
which in turn contributes to renal sympathetic activation and its
related pressor effect and increased HR [18]. Increased activity
of neurons in the RVLM contributes to experimental and
essential HTN [28]. Overactivity of the sympathetic nervous
system is one of the more important causes of essential HTN
[32] and contributes to the pathogenesis of HTN and progres-
sion of organ damage [33]. There is a possibility that the
salusins act on the central nervous system to decrease sympa-
thetic nerve activity and arterial pressure [26]. Zhang et al.
discovered that neither circulating AVP nor AVP in the RVLM
is involved in the sympatho-excitatory and pressor effects of
salusin-β in the RVLM [18]. There is also a possibility that the
RAS may be involved in the pressor response to salusin-β in
the RVLM because the brain RAS is known to be activated in
this model of HTN [34–36].
Our results show that children with essential HTN had
higher plasma salusin-β levels than children with white-coat
hypertension enrolled in a reference group. It therefore seems
possible that future comparisons of children with essential
HTN and healthy children may reveal that this difference is
more significant than the that found in our study. Unfortunate-
ly, no published data are currently available in this area,
although intravenous salusin-β administration to intact anes-
thetized rats has been found to cause hypotension and brady-
cardia [1]. More research on this topic needs to be undertaken
because the mechanism of this result is still unknown.
Evidence recently emerging from animal and human stud-
ies shows a clear association between novel salusin peptides
and atherosclerosis [2], as well as the important roles of these
peptides as endogenous modulators of atherogenesis [8]. Ath-
erosclerosis is a complex and multifactorial disease whose
pathogenesis is associated with inflammatory responses [37,
38]. It has been reported that the endogenous salusin-β exces-
sively produced in vascular lesions could contribute to the
development of atherosclerosis [2, 11, 39]. Salusin-β is re-
leased from humanmonocytes/macrophage, suggesting a pos-
sible autocrine/paracrine role in the development and progres-
sion of atherosclerosis [8, 22]. The development of athero-
sclerosis is influenced by abnormalities in cellular cholesterol
homeostasis in subendothelial macrophages [12]. The TG)/
HDL-cholesterol ratio has been reported to be a useful marker
of atherogenic lipid abnormalities, insulin resistance, and car-
diovascular disease [40, 41]. Consequently, the TG/HDL ratio
may help identify children and adolescents at high risk for
structural vascular changes and metabolic derangement [41].
In our study we derived a positive correlation between serum
salusin-β level and the TG/HDL ratio. Additionally, we found
higher salusin-β plasma levels in obese children which was
Fig. 5 Correlation serum
salusin-β level and TG/HDL ratio
(rho=0.22, p<0.05). HDL High-
density lipoprotein-cholesterol
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positively correlated with the BMI Z-score. Unfortunately,
there are currently no research results available in this area.
To summarize, our results, while preliminary, suggest that
salusin-β, but not salusin alpha, may play an important role in
the pathogenesis of HTN in the pediatric populations. However,
we recommend that further research be undertaken to assess the
role of salusin-β in the mechanism of essential HTN and the
possible correlations between salusin-β and other well-known
markers of atherosclerosis in both teenagers and adults. Our
studywill hopefully serve as a base for future studies in this field.
Finally, a number of important limitations need to be consid-
ered. First, the reference group was not a group of healthy
teenagers, but a group of patients in whom HTN was not
confirmed in the 24-hABPM; consequently, we considered these
subjects to belong to the white-coat HT group. Secondly, the two
study groups clearly differed, with the hypertensive group (HTN)
predominantly consisting of adolescent males, most of whom
had a high BMI Z-score, and the reference group (R) primarily
consisting of slender girls with white-coat HT.
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